N/A N=10 Assessment of Limb Perfusion During Junctional Tourniquet
Bleeding
Primary: Muscle Perfusion — 0.32; 0.10 IU/s
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=3,372 Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Tetanus · Diphtheria · Pertussis
Primary: Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine — 240; 222; 242; 217…
N/A N=151 Evaluation of Accelerated Partial Breast Brachytherapy
Breast Cancer
Primary: Local Control Using Ipsilateral Breast Tumor Recurrence Rates — .7 percentage of participants
Phase 3 N=412 Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Breast Cancer
Primary: Number of Participants With Acute Radiation Toxicities Recorded According to Radiation Therapy Oncology Group (RTOG) — 22; 16 participants
N/A N=125 Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients
Vitamin B12 Deficiency
Primary: Prevalence of Vitamin B12 Deficiency — 3; 6; 4 participants
N/A N=100 Effect of Buffered Numbing Solution on Patients With Toothaches
Irreversible Pulpitis (Toothache)
Primary: Percent of Patients With Successful Anesthesia (% of Patients Able to Have Treatment Without Additional Anesthesia) — 16; 20 Participants
N/A N=46 Neurologic Injuries in Adults With Urea Cycle Disorders
Brain Diseases, Metabolic, Inborn · Urea Cycle Disorder · Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003
Phase 3 N=2,018 Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Anemia
Primary: Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC. — 6; 22 participants
Phase 2 N=142 Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer
Breast Neoplasms
Primary: Progression Free Survival — 1.2; 1.3 years
N/A N=4 A Study of Dental Implants Coated With Bone Morphogenetic Protein
Alveolar Ridge Abnormality
Primary: Primary Endpoint Was to Assess Implant Stability of the Implants( 4 Patients in Two Groups With a Total of 8 Implants) at Baseline and After 3 Months of Submerged…
Phase 3 N=543 Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
Renal Failure
Primary: The Primary Efficacy Endpoint for the Study is the Proportion of Treatment Failures Within 12 Months After Randomization to Study Drug. — 8; 8; 9; 11 participants…
Phase 3 N=738 Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
Moderate to Severe Plaque-type Psoriasis
Primary: Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks — 71.6; 81.6; 4.5 Percentage of participants
Phase 1 N=10 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
Neuromyelitis Optica · Neuromyelitis Optica Spectrum Disorder
Primary: Baseline Expanded Disability Status Score (EDSS) — 3.5 units on a scale
Phase 2 N=173 Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores
Recurrent Herpes Labialis
Primary: Clinician Assessed Duration of Complete Healing of the Herpetic Episode — 129.6; 154.6 hours
Phase 2 N=61 Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Hepatitis C · Hepatocellular Carcinoma
Primary: Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12 — 75.0; 69.8 percentage of participants